Incyte Corporation · NASDAQ:INCY
Incyte — ASCO Gastrointestinal Cancers Symposium 2026
16 slides from Incyte's conference presentation, January 2026
Slide 1: Preliminary Phase 1 Results of INCB161734 in Advanced/Metastatic PDAC
Preliminary Phase 1 Results of INCB161734, a Novel Oral Kirsten Rat Sarcoma (KRAS) G12D Inhibitor, as Monotherapy or in Combination With Chemotherapy for Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Zev Wainberg,' Jason Henry,? Haeseong Park,? Rasha Cosman,’ Manuel Hidalgo Medina,* Da
Slide 2: Key Takeaway Points
Key Takeaway Points e INCB161734 monotherapy demonstrates a favorable safety and efficacy profile at the RP2D of 1200 mg qd e INCB161734 at 1200 mg qd demonstrates tolerability with SoC chemotherapy (GEMNabP or mFOLFIRINOX) in patients with metastatic PDAC, without compromising chemotherapy dose int
Slide 3: Introduction
Introduction e KRASS'!20 mutations are among the most common e INCB161734 is a novel, selective ON/OFF oral KRASS120 oncogenic drivers for PDAC, CRC, and nsNSCLC' inhibitor: — Exhibited >80-fold selectivity over KRAS“™ — Demonstrated robust monotherapy antitumor activity WS and enhanced tumor growth
Slide 4: INCB161734-101 (NCT06179160): Study Design
INCB161734-101 (NCT06179160): Study Design Key Eligibility Criteria (All Groups) + Locally advanced or metastatic solid tumor with KRAS®!20 mutation + ECOG PS Oor 1 + No prior treatment with a KRASS' selective inhibitor Key Eligibility Criteria (Chemotherapy Combinations in PDAC) + Dose escalation:
Slide 5: PDAC Patient Disposition and Baseline Characteristics
PDAC Patient Disposition and Baseline Characteristics e As of November 11, 2025, 61 patients with PDAC received single agent INCB161734 1200 mg qd — Treatment ongoing in 42 (69%) — Primary reason for discontinuation was disease progression (n=14; 23%) e 28 patients received INCB161734 in combination
Slide 6: INCB161734 Was Well Tolerated as 1200 mg qd Monotherapy
INCB161734 Was Well Tolerated as 1200 mg qd Monotherapy in Patients With KRAS°129-Mutated PDAC e 2 patients (3%) discontinued treatment due to TRAEs © 6 patients (10%) had dose reductions due to TRAEs — Most common TRAE leading to dose reduction was fatigue (n=2) e 13 patients (21%) had dose interru
Slide 7: INCB161734 Monotherapy Showed Encouraging Antitumor Activity in Heavily Pretreated Patients
INCB161734 Monotherapy Showed Encouraging Antitumor Activity in Heavily Pretreated Patients With PDAC e High ORR and DCR for patients with PDAC (mainly 3L+) who received INCB161734 1200 mg daily* 100 1200 mg daily 1200 mg daily ey — Ongoing (n=41) 60-4 DCR,t % (n) 78% (32) ORR,* % (n) 37% (15) a? SD
Slide 8: Swimmer Plot Indicates Clinical Benefit Is Durable
Swimmer Plot Indicates Clinical Benefit Is Durable in Heavily Pretreated Patients With PDAC Patients —$S_.—7 1200 mg daily* 2 » Ppt een Sa | spt ——$ {‘{_ © PRt a Tr > Ongoing * 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 Treatment Duration, Weeks “INCB1
Slide 9: INCB161734 in Combination With GEMNabP Was Well Tolerated
INCB161734 in Combination With GEMNabP Was Well Tolerated Without Compromising Chemotherapy Dose Intensity e 46% of patients were 2L and had received prior systemic chemotherapy e Median RDI was 74% for both gemcitabine and nab-paclitaxel TRAEst — Comparable to previous reports for GEMNabP regimen’
Slide 10: INCB161734 in Combination With mFOLFIRINOX Was Well Tolerated
INCB161734 in Combination With mFOLFIRINOX Was Well Tolerated Without Compromising Chemotherapy Dose Intensity e 31% of patients were 2L and had received prior systemic chemotherapy e Median RDI was 76% for fluorouracil, 67% for irinotecan, and 67% for oxaliplatin TRAEst — Comparable to previous rep
Slide 11: INCB161734 With SoC Chemotherapy Showed Encouraging Antitumor Activity
INCB161734 With SoC Chemotherapy Showed Encouraging Antitumor Activity in Patients With 1L or 2L Metastatic PDAC 100 600 mg qd + 1200 mg qd + 804 #600 mg qd_# 1200 mg qd chemotherapy chemotherapy — Ongoing {pete} fore) 605 DCR, % (n) 87% (13) 88% (7) 407 ORR, % (n) 27% (4) 50% (4) Best Change From B
Slide 12: Measurement of KRAS G12D in Plasma ctDNA Confirmed Rapid Molecular Responses
Measurement of KRAS®°'22 in Plasma ctDNA Confirmed Rapid Molecular Responses e INCB161734 at 2600 mg qd dose caused Best Change in VAF (PDAC) rapid molecular responses coal ‘ ° Cy li e Inpatients with PDAC with detectable $s 7 ° * ° KRAS®"?° in plasma ctDNA (79%), Z* 904 66% receiving a 1200 mg dose
Slide 13: Early Clinicogenomic Profiling
ASCO Gastrointestinal Cancers Symposium Early Clinicogenomic Profiling Baseline Genomic Profiles (Tissue + Plasma ctDNA NGS) PR ey) PD =z EE £0R fF FEF 8 ME data available 2222222222929222 22M2 2M 232 si lalle lass a2 KAS CN 79% rit oe wee cae pies Beg moc men CoKwzA 25% 4s TAP 23% a ' 7a SMAD4 18%
Slide 14: Conclusions
Conclusions e Results show a favorable safety profile of INCB161734 as monotherapy at 1200 mg ad, with few dose interruptions and reductions — GI TRAEs were mostly grade 1 and improved during treatment e Safety data of INCB161734 at RP2D of 1200 mg qd in combination with GEMNabP or mFOLFIRINOX in pa
Slide 15: Future Direction
Future Direction e DAWN-303 global phase 3 study in patients with 1L metastatic PDAC initiating in 2026 mFOLFIRINOX or GEMNabP + INCB161734 Treatment until PD 30-day safety follow-up and overall Treatment survival until PD Key Eligibility Criteria » Metastatic PDAC with locally or centrally determin
Slide 16: Acknowledgments
Acknowledgments The authors wish to thank the patients and their families, the investigators, and the site personnel who participated in this study. This study was sponsored by Incyte Corporation (Wilmington, DE, USA). Medical writing assistance was provided by Alasdair Gunn, DPhil, of Envision Igni
Incyte — ASCO Gastrointestinal Cancers Symposium 2026 on 6ix